Cryoport, Inc. (NASDAQ:CYRX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Cryoport, Inc. (NASDAQ:CYRX) has been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $11.00.

CYRX has been the topic of several recent analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of Cryoport in a research note on Thursday, May 8th. Morgan Stanley dropped their price objective on Cryoport from $8.00 to $7.00 and set an “equal weight” rating for the company in a research note on Monday, May 5th. Roth Mkm restated a “buy” rating and set a $15.00 target price on shares of Cryoport in a research report on Tuesday, April 1st. UBS Group raised their price target on Cryoport from $10.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, April 1st. Finally, Guggenheim reiterated a “buy” rating and set a $10.00 price target on shares of Cryoport in a research report on Wednesday, April 16th.

Cryoport Stock Performance

Shares of CYRX stock opened at $6.04 on Tuesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. The firm has a market cap of $302.83 million, a price-to-earnings ratio of -1.79 and a beta of 1.92. Cryoport has a 52 week low of $4.58 and a 52 week high of $11.64. The firm’s 50-day simple moving average is $5.94 and its two-hundred day simple moving average is $6.80.

Cryoport (NASDAQ:CYRX) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. The company had revenue of $41.04 million during the quarter, compared to analyst estimates of $56.19 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. As a group, equities analysts forecast that Cryoport will post -0.99 earnings per share for the current year.

Insider Buying and Selling at Cryoport

In other news, CEO Jerrell Shelton sold 4,620 shares of Cryoport stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the completion of the transaction, the chief executive officer now directly owns 765,399 shares in the company, valued at approximately $4,814,359.71. This trade represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have sold 19,830 shares of company stock valued at $118,353. 10.00% of the stock is currently owned by company insiders.

Institutional Trading of Cryoport

Several institutional investors have recently added to or reduced their stakes in CYRX. Franklin Resources Inc. boosted its holdings in Cryoport by 0.4% in the fourth quarter. Franklin Resources Inc. now owns 387,131 shares of the company’s stock worth $3,012,000 after purchasing an additional 1,512 shares during the last quarter. Rhumbline Advisers lifted its holdings in Cryoport by 2.9% during the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company’s stock valued at $492,000 after purchasing an additional 1,764 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its position in shares of Cryoport by 148.7% in the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock worth $28,000 after purchasing an additional 2,120 shares during the period. Sierra Summit Advisors LLC increased its stake in shares of Cryoport by 5.0% in the first quarter. Sierra Summit Advisors LLC now owns 45,060 shares of the company’s stock worth $274,000 after purchasing an additional 2,150 shares in the last quarter. Finally, Nebula Research & Development LLC increased its stake in shares of Cryoport by 21.6% in the fourth quarter. Nebula Research & Development LLC now owns 12,442 shares of the company’s stock worth $97,000 after purchasing an additional 2,207 shares in the last quarter. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.